Home Hematologic Conditions

Hematologic Conditions

Latest

cell survival protein

Hematologic Conditions

Potential Protein Protection for Kidneys from Cancer Therapies Discovered

Hematologic Conditions

Chimerix Licenses Cantex’s CX-01 for AML after Promising Phase II Results

Hematologic Conditions

After 2 Patient Deaths, FDA Imposes Partial Clinical Hold on Trial of Xencor Blood Cancer Antibody XmAb14045

Hematologic Conditions

AMAG Pharmaceuticals to Acquire Perosphere Pharmaceuticals

Harbour BioMed will partner with Sichuan Kelun-Biotech Biopharmaceutical to develop and commercialize its Phase II cancer immunotherapy candidate A167 worldwide except greater China. The antibody is envisioned for use in a broad range of solid tumor and hematological malignancies

Hematologic Conditions

Harbour BioMed to Develop Kelun-Biotech’s Cancer Immunotherapy Candidate A167

Recent research uncovers a new approach for expanding blood-forming

Hematologic Conditions

Reversible Technique Developed for Stem Cell Expansion

Hematologic Conditions

Curcumin Shown to Inhibit DYRK2 and Reduce Cancer Burden

Synthetic biologists at the University of Bristol have succeeded in generating laboratory-made red blood cells with rare blood group types. [Dr. Ashley Toye/University of Bristol]

Hematologic Conditions

CRISPR Improves Red Blood Cell Transfusion Success

Hematologic Conditions

Model Wound System Created that Self Heals

Hematologic Conditions

Shire Hemophilia Candidate Using Xenetic Platform Falls Short in Trial

Hematologic Conditions

Nohla and UC Davis Ink Manufacturing Deal for Off-the-Shelf Donor Stem...

Hematologic Conditions

Novartis Acquires Selexys Pharmaceuticals

Hematologic Conditions

Takeda to Co-Develop Gencia’s MAGR Drugs in Up-to-$500M+ Partnership

Hematologic Conditions

Blood-Cleansing Biospleen Developed